Cefprozil, (E)-
The E-geometric isomer of cefprozil is the active component of this oral second-generation cephalosporin antibiotic used for respiratory and skin infections. It has activity against both gram-positive organisms like Streptococcus and gram-negative organisms like Haemophilus influenzae. It is generally well tolerated with a safety profile similar to other oral cephalosporins.
น้ำหนักโมเลกุล
407.4000 g/mol
TPSA
159.00 Ų
กลไกการออกฤทธิ์
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
โครงสร้าง 2 มิติ
Cite this structure
Embed this structure
SMILES
C/C=C/C1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1.O
InChI
InChI=1S/C18H19N3O5S.H2O/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9;/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26);1H2/b3-2+;/t12-,13-,17-;/m1./s1
Molecular Formula
C18H21N3O6S
HBD / HBA
5 / 8
พันธะที่หมุนได้
5
อะตอมหนัก
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
คำถามที่พบบ่อย
The E-geometric isomer of cefprozil is the active component of this oral second-generation cephalosporin antibiotic used for respiratory and skin infections. It has activity against both gram-positive organisms like Streptococcus and gram-negative organisms like Haemophilus influenzae. It is generally well tolerated with a safety profile similar to other oral cephalosporins.
Disrupts bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis. The resulting cell wall defects cause osmotic instability and bacteriolysis.
Yes, Cefprozil, (E)- is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314373. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 6436628. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
ข้อจำกัดความรับผิดชอบทางการแพทย์
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cefprozil-e"></div>
Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cefprozil-e/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>
Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cefprozil-e/
Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cefprozil-e/)
Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cefprozil-e"></drugfyi-drug>